Bryan J. McMichael - 07 Sep 2022 Form 3 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Officer
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Bryan J. McMichael
Issuer symbol
CHRS
Transactions as of
07 Sep 2022
Net transactions value
$0
Form type
3
Filing time
09 Sep 2022, 17:36:25 UTC
Next filing
06 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CHRS Common Stock 15,584 07 Sep 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CHRS Stock Option (Right to Buy) 07 Sep 2022 Common Stock 100,000 $14.76 Direct F2
holding CHRS Stock Option (Right to Buy) 07 Sep 2022 Common Stock 25,000 $14.67 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 12,500 restricted stock units.
F2 The underlying shares subject to the option vest and become exercisable as to 25% on the one year anniversary measured from the grant date and 1/48th of the shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F3 The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from the grant date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Remarks:

Title: Senior Vice President, Accounting, Corporate Controller and Principal Accounting Officer Exhibit 24.1 - Power of Attorney